The performance of Japanese pharmaceutical companies in China obviously cannot catch up with the footsteps of European and American companies' development，Now，Reinstalling the lost Chinese market has become the primary choice for Japanese pharmaceutical companies to maintain performance -

　　

"I hope everything will come from scratch。"Valley Leisure History lamented when talking about the Chinese market。Facing the rapidly growing Chinese market，Global pharmaceutical companies have grabbed beaches，This also includes a number of Japanese pharmaceutical companies。The earliest Japanese companies who came to China "got up early，Kait a late set "，After 30 years of competition，Japanese companies' performance in China obviously cannot catch up with the footsteps of European and American companies。

With the expiration of the patented medicine，The days of Japanese pharmaceutical companies are very difficult，To achieve performance improvement，Japanese companies have used the Chinese market as a "life -saving straw" for the rise of performance。Following Asta Lai to announce its "Tengyue Plan" launched for the Chinese market in the next five years，Takeda Pharmaceutical, which has poor performance this year, also pinned the hope of growth in the Chinese market。

stake online sports bettingIn stake betting apprecent years，Takeda Pharmaceutical's development in China is not ideal，2007 ～ 2009 continuous loss，The amount of loss has reached 109.267 million yuan，So，How to get rid of the predicament has become its very difficult problem。

Current，Returning to the lost Chinese market has become the primary choice for Japanese companies to maintain performance growth。

Japan's largest pharmaceutical dealer Takeda Pharmaceutical CEO Hasegawa History revealed in an interview with the media a few days ago，The company is planning to plan Chinese business for the next 10 years，To get rid of the situation with poor current revenue。

Japan's second largest pharmaceutical dealer -the CEO of Anstelai Pharmaceutical Group's CEO wild Musta Yayu also clearly stated: "It will increase its pioneering efforts to the Asian market，Focus on expanding the business of the Chinese market。”

"Salted Fish Turn over"?

For the past few decades，The focus of Japanese pharmaceuticals has always been placed on the development of the country's market。Most of them are the original pharmaceutical companies，The main profit comes from the new drug independently developed。For overseas markets，The common practice of Japanese pharmaceutical companies is to authorize sales，Mainly relying on the marketing team of foreign companies to sell their products，But as the patent expires、Effects of intense competition，This mode is becoming more and not suitable for the market。

Among the Japanese companies in China，Takeda Pharmaceutical's performance is the most unsatisfactory。Public information display，Tianjin Takeda continuously lost money between 2007 ～ 2009，The amount of loss has reached 109.267 million yuan，From January to June 2010, I still lose money，The amount reaches 23.37 million yuan，The loss of 12.39 million yuan from the same period last year。Li Sheng Pharmaceutical's current long -term equity investment has been 414.288 million yuan from initial investment，reduced to 23.838 million yuan Stake Sports Bettingat the end of 2009，shrinking 57.53%。

My stake betting appThe poor performance makes its Chinese partners even plans to give up the continued joint venture。

September 10 this year，Tianjin Lisheng Pharmaceutical Co., Ltd. has transferred 25%of the equity of Tianjin Takeda Pharmaceutical Co., Ltd.。Title of Lisheng Pharmaceuticals，If it can be successfully transferred，Not only can it restore the losses previously on the company's participating company，You can also get a lot of investment income。

The embarrassing performance encountered by Takeda is not just in the Chinese market，Its global performance is not ideal。Take Takeda as an example，According to its performance report released in the middle of the year，Net income dropped by 43.1%，Fall to 64.11 billion yen，About 740 million US dollars，and the total sales decreased by 6.4%，to 354.7 billion yen。It also lost the gastrointestinal drug Lanzozole's patent protection in the United States，The latter's sales fell 44.6%to 38.7 billion yen。

At the same time，Astai Lai's days are not good，The company's global performance has declined for 3 consecutive years。Due to the impact of generic drugs，Asta Lai's star product -Pu Leko's sales fell 7.1%，In 2009, the company's operating income decreased by 25.6%compared to 2008。Local in Japan，The price of drug prices brought by the National Health Insurance Plan decreases，The overall sales of its company in 2010 are expected to decrease by 3.6%。

Comparison of comparison，The performance growth ability of the Chinese market is more attractive to Japanese companies。According to Zhuo Yongqing, general manager of Ansai to China，Ansai came to China to occupy 43%of its Asian Division。

For Japanese companies，The importance of the Chinese market is accompanied by the decline in the overall performance of Japanese companies.，How to "turn over" in the Chinese market as soon as possible to become the first task of Japanese companies。

　　

Not good management

Always，The performance of Japanese companies mainly relies on the local market in the United States My stake betting appand Japan，But with many patented My stake betting appmedicines expired，Japanese National Health Insurance Plan further reduces drug prices，The value of the Chinese market is highlighted，Japanese companies that have always paid attention to the Chinese market，It has also started new plans for the Chinese market。

But it is understood，In recent years, the drugs of Takeda Pharmaceuticals have not sold well in China，Especially its main antichen cephalosporin and diabetes medicine Aikoto。Current，Domestic girosteen has occupied about 80%of the clinical share。and Shanghai New Pioneer Pharmaceutical、Harbin Pharmaceutical Group Pharmaceutical General Pharmaceuticals and other enterprises all have production，and companies are applying for production。

Aikoto has since entered the Chinese market in 2004，Selling in China in the past 5 years has not been high。But last year Aikoto's global sales reached 4 billion US dollars，The top of the global anti -diabetic drug sales list。

Current，Aikoto of Takeda Pharmaceutical only expands product sales through Pfizer's existing business coverage，The fixed ratio in its net sales will be used as a pump into Pfizer China Company，This shows the disadvantage of Japanese companies in marketing。

"The performance of the joint venture company is worrying，It is due to the poor management of Takeda Pharmaceutical，The company's production and promotion of several products in China did not achieve the success of the expected。"History of Hasegawa Leisure Consid by，"The company needs to arrange strong management and sales teams in China，and this part of the business If the plan is successful，The company's operating income in China will increase by 10 times。”

At the same time，Anstela, who has maintained steadily in the Chinese market, is also increasing investment，Make the sales of the Chinese market flippage in the fiscal year as of March 2015。

In addition，These two Japanese companies will also expand their operating scale and marketing team on a large scale。2010，Anstelai will hire at least 300 salespersons in China，and the function stake online sports bettingand training system of the My stake betting apppersonnel of each section will be strengthened，Reform of the salary system and information system，At the same time，Perform budget rights and accounting system reform。

Uniqueness，Takeda is also recruiting soldiers in Dalian，The position recruited this time in China includes research and development、Production Technology、official technology、Medical Business、International business and comprehensive positions。In the recruitment instructions，The company listed the holding of new employees、Promise in development space such as welfare benefits and job promotion such as paid annual leave。